| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 3, 2021 | PFE Pfizer Inc | Johnson Rady A | Executive Vice President | Sell | 19,000 | $53.42 | $1,015,041.96 | -2.4% | -11.2% | -3.1% | |
| Dec 3, 2021 | ORGO Organogenesis Holdings Inc. | Katz Michael W | 10% Owner | Buy | 2,600 | $9.57 | $24,870.00 | +1.5% | -7.7% | -71.5% | |
| Dec 2, 2021 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $189.36 | $1,136,140.14 | -3.7% | -7.4% | +47.2% | |
| Dec 2, 2021 | AMRX Amneal Pharmaceuticals, Inc. | Todisco Joseph76 | Executive Vice President | Sell | 1,500 | $4.10 | $6,150.00 | -0.5% | -3.6% | -41.7% | |
| Dec 2, 2021 | PRGO Perrigo Co Plc | Classon Rolf A | Director | Buy | 2,800 | $35.67 | $99,874.04 | +19.1% | +6.3% | -8.2% | |
| Dec 2, 2021 | PFE Pfizer Inc | MacKenzie Alexander R | Executive Vice President | Sell | 41,360 | $54.26 | $2,244,193.60 | -32.2% | -9.4% | -0.9% | |
| Dec 1, 2021 | NBIX Neurocrine Biosciences Inc | Abernethy Matt57 | Chief Financial Officer | Sell | 1,645 | $82.59 | $135,852.49 | -9.1% | +13.7% | +56.3% | |
| Nov 30, 2021 | TXMD Therapeuticsmd, Inc. | Donegan Michael C85 | CAO And VP Of Finance | Sell | 29,790 | $0.54 | $15,946.59 | -23.1% | -51.7% | -81.5% | |
| Nov 30, 2021 | ELAN Elanco Animal Health Inc | Hoover R David50 | Director | Buy | 10,000 | $29.38 | $293,794.00 | +10.5% | -1.1% | -55.2% | |
| Nov 30, 2021 | BHC Bausch Health Companies Inc. | Miller Steven D | Director | Buy | 60,000 | $24.23 | $1,453,524.00 | +556.6% | +0.9% | -70.5% | |
| Nov 30, 2021 | ELAN Elanco Animal Health Inc | Harrington Michael J | Director | Buy | 2,500 | $29.25 | $73,122.50 | +9.7% | -1.1% | -55.2% | |
| Nov 30, 2021 | CPIX Cumberland Pharmaceuticals Inc | Kazimi A J59 | Chairman And CEO | Buy | 395 | $2.75 | $1,085.90 | - | -37.6% | -54.9% | |
| Nov 30, 2021 | CPIX Cumberland Pharmaceuticals Inc | Young Caroline52 | Director | Buy | 395 | $2.75 | $1,085.90 | +0.1% | -37.6% | -54.9% | |
| Nov 30, 2021 | CPIX Cumberland Pharmaceuticals Inc | Jones James53 | Director | Buy | 882 | $2.72 | $2,401.56 | +0.2% | -37.6% | -54.9% | |
| Nov 30, 2021 | CPIX Cumberland Pharmaceuticals Inc | Cearnal Martin E47 | Sr Vp/ Chief Commercial Officer | Buy | 2,485 | $2.74 | $6,802.60 | - | -37.6% | -54.9% | |
| Nov 30, 2021 | CPIX Cumberland Pharmaceuticals Inc | Krogulski Kenneth55 | Director | Buy | 2,045 | $2.74 | $5,604.50 | - | -37.6% | -54.9% | |
| Nov 29, 2021 | ORGO Organogenesis Holdings Inc. | Katz Michael W | 10% Owner | Buy | 1,000 | $9.75 | $9,750.00 | +1.8% | -23.8% | -72.5% | |
| Nov 29, 2021 | PTPI Petros Pharmaceuticals, Inc. | Shulman John D | Director, 10% Owner | Buy | 500,000 | $3.00 | $1,500,000.00 | +9.9% | - | - | |
| Nov 26, 2021 | ZTS Zoetis Inc. | Peck Kristin C66 | Chief Executive Officer | Sell | 14,500 | $223.10 | $3,234,955.00 | -8.6% | -12.8% | -31.1% | |
| Nov 26, 2021 | PFE Pfizer Inc | Lankler Douglas M | Executive Vice President | Sell | 40,000 | $54.37 | $2,174,786.23 | -3.5% | -14.2% | -5.9% | |
| Nov 26, 2021 | PFE Pfizer Inc | Susman Sally | Executive Vice President | Sell | 44,308 | $54.52 | $2,415,577.60 | -2.4% | -14.2% | -5.9% | |
| Nov 26, 2021 | ORGO Organogenesis Holdings Inc. | Katz Michael W | 10% Owner | Buy | 2,000 | $9.79 | $19,570.00 | +1.8% | -27.8% | -72.1% | |
| Nov 24, 2021 | BCRX Biocryst Pharmaceuticals Inc | Milano Vincent | Director | Buy | 7,500 | $12.19 | $91,425.00 | +75.0% | +42.0% | -1.8% | |
| Nov 24, 2021 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 3,083 | $200.64 | $618,573.12 | -96.0% | -3.2% | +33.9% | |
| Nov 24, 2021 | BMY Bristol Myers Squibb Co | Von Autenried Paul | EVP, Chief Information Officer | Sell | 51,134 | $57.18 | $2,923,617.93 | -17.5% | +19.8% | +43.8% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.